Preliminary Assessment of Galectin-3 Expression in Serum and Follicular Fluid: Implications for Predicting In Vitro Fertilization Outcomes.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
Oct 2024
Historique:
medline: 14 10 2024
pubmed: 14 10 2024
entrez: 14 10 2024
Statut: ppublish

Résumé

Galactin-3 has been found to be involved in oocyte maturation, folliculogenesis, implantation, and placentation. The expression of Galactin-3 in the endometrium of women who have successfully undergone in vitro fertilization (IVF) has been suggested as a potential biomarker for predicting successful embryo implantation. To evaluate the expression of Galactin-3 in the sera and follicular fluid of women during IVF cycles. This prospective research included 21 women undergoing IVF treatments. Blood samples were taken at four points: day 2 before starting stimulation, trigger day, day of oocyte retrieval, and day of the β-human chorionic gonadotropin level test. In addition, follicular fluid samples were taken on the day of oocyte retrieval. Galactin-3 protein levels were measured in serum and follicular fluid using enzyme-linked immunosorbent assay. Galactin-3 levels on the stimulation day were positively correlated to estradiol levels on the day of the trigger (0.59, P = 0.02). Among women who achieved pregnancy compared to those who did not, Galectin-3 serum levels were higher on the day of the trigger (17.93 ± 4.35 ng/ml vs. 11.01 ± 3.73 ng/ml, P = 0.015). These findings may imply a potential role of Galectin-3 on the success of IVF treatments, underscoring the potential importance of inflammatory processes in fertility.

Sections du résumé

BACKGROUND BACKGROUND
Galactin-3 has been found to be involved in oocyte maturation, folliculogenesis, implantation, and placentation. The expression of Galactin-3 in the endometrium of women who have successfully undergone in vitro fertilization (IVF) has been suggested as a potential biomarker for predicting successful embryo implantation.
OBJECTIVES OBJECTIVE
To evaluate the expression of Galactin-3 in the sera and follicular fluid of women during IVF cycles.
METHODS METHODS
This prospective research included 21 women undergoing IVF treatments. Blood samples were taken at four points: day 2 before starting stimulation, trigger day, day of oocyte retrieval, and day of the β-human chorionic gonadotropin level test. In addition, follicular fluid samples were taken on the day of oocyte retrieval. Galactin-3 protein levels were measured in serum and follicular fluid using enzyme-linked immunosorbent assay.
RESULTS RESULTS
Galactin-3 levels on the stimulation day were positively correlated to estradiol levels on the day of the trigger (0.59, P = 0.02). Among women who achieved pregnancy compared to those who did not, Galectin-3 serum levels were higher on the day of the trigger (17.93 ± 4.35 ng/ml vs. 11.01 ± 3.73 ng/ml, P = 0.015).
CONCLUSIONS CONCLUSIONS
These findings may imply a potential role of Galectin-3 on the success of IVF treatments, underscoring the potential importance of inflammatory processes in fertility.

Identifiants

pubmed: 39397501

Substances chimiques

Galectin 3 0
Biomarkers 0
Estradiol 4TI98Z838E
LGALS3 protein, human 0
Galectins 0
Blood Proteins 0

Types de publication

Journal Article Interview

Langues

eng

Sous-ensembles de citation

IM

Pagination

560-565

Auteurs

Gili Kroitoro Man-El (G)

Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Amir Wiser (A)

Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Ishai Heusler (I)

Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Sydney Benchetrit (S)

Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Netanella Miller (N)

Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Tal Biron-Shental (T)

Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Tali Zitman-Gal (T)

Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Einat Haikin Herzberger (E)

Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH